Last Funding Type: Post-IPO Equity
Funding Status: M&A
Headquarters: London, England, United Kingdom
Founded Date: 2013
Investor Type: Company
Investment Stage: N/A
Total Funding: $174.6M
Technology: Neurological Disorders
Employee Number: 11-50
Number Of Exists: Post-IPO Equity
Estimated Revenue: $1M to $10M
Investors Number: 4
Industry: Gene Therapy